Top Markets
#1 Akedo Akedo +89.15%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.04%
#4 Cross Cross +45.95%
#5 Black Phoenix Black Phoenix +34.04%
#6 Velvet Velvet +33.27%
#7 OVERTAKE OVERTAKE +20.49%
#8 Illuvium Illuvium +18.60%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.91%
#10 Cap Cap +15.95%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Exopharm Limited Exopharm Limited

Exopharm Limited

EX1
Classifica tra le azioni #39130
Exopharm Limited is an Australian clinical-stage firm dedicated to developing... Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
Prezzo delle azioni
$0.00700343
Ultima sincronizzazione: 2023-10-30
Capitalizzazione di mercato
$637.31K
Variazione (1 giorno)
0.50%
Variazione (1 anno)
0.00%
Paese
AU
Scambia Exopharm Limited (EX1)

Categoria

Healthcare
Ricavi di Exopharm Limited (EX1)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Exopharm Limited, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Exopharm Limited da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE